© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 3, 205-216,
February 2, 2000
© 2000 Oxford University Press
SPECIAL ARTICLE |
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Affiliations of authors: P. Therasse, J. Verweij, M. Van Glabbeke, A. T. van Oosterom, European Organization for Research and Treatment of Cancer, Brussels, Belgium; S. G. Arbuck, R. S. Kaplan, L. Rubinstein, M. C. Christian, National Cancer Institute, Bethesda, MD; E. A. Eisenhauer, National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada; J. Wanders, New Drug Development Office Oncology, Amsterdam, The Netherlands; S. G. Gwyther, East Surrey Healthcare National Health Service Trust, Redhill, U.K.
Correspondence to: Patrick Therasse, M.D., European Organization for Research and Treatment of Cancer Data Center, Avenue Mounier 83/11, 1200 Brussels, Belgium (e-mail: pth{at}eortc.be).
Anticancer cytotoxic agents go through a process by which their antitumor activityon the basis of the amount of tumor shrinkage they could generatehas been investigated. In the late 1970s, the International Union Against Cancer and the World Health Organization introduced specific criteria for the codification of tumor response evaluation. In 1994, several organizations involved in clinical research combined forces to tackle the review of these criteria on the basis of the experience and knowledge acquired since then. After several years of intensive discussions, a new set of guidelines is ready that will supersede the former criteria. In parallel to this initiative, one of the participating groups developed a model by which response rates could be derived from unidimensional measurement of tumor lesions instead of the usual bidimensional approach. This new concept has been largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines. This special article also provides some philosophic background to clarify the various purposes of response evaluation. It proposes a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment. Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate.
Correspondence about this Article
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
- Ignace Vergote, Gordon J. S. Rustin, Elisabeth A. Eisenhauer, Gunnar B. Kristensen, Eric Pujade-Lauraine, Mahesh K. B. Parmar, Michael Friedlander, Anders Jakobsen, and Jan B. Vermorken
J Natl Cancer Inst 2000 92: 1534-1535.[Extract] [Full Text] [PDF]
- Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
- Gordon J. S. Rustin, Michael Quinn, Tate Thigpen, Andreas du Bois, Eric Pujade-Lauraine, Anders Jakobsen, Elizabeth Eisenhauer, Satoru Sagae, Kathryn Greven, Ignace Vergote, Andres Cervantes, and Jan Vermorken
J Natl Cancer Inst 2004 96: 487-488.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
![]() |
S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al. Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer N. Engl. J. Med., July 3, 2008; 359(1): 31 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, et al. Detection of Mutations in EGFR in Circulating Lung-Cancer Cells N. Engl. J. Med., July 2, 2008; (2008) NEJMoa0800668v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Cohen, C. J.A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. Morse, E. Mitchell, M. C. Miller, et al. Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer J. Clin. Oncol., July 1, 2008; 26(19): 3213 - 3221. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. P. Worden, B. Kumar, J. S. Lee, G. T. Wolf, K. G. Cordell, J. M.G. Taylor, S. G. Urba, A. Eisbruch, T. N. Teknos, D. B. Chepeha, et al. Chemoselection As a Strategy for Organ Preservation in Advanced Oropharynx Cancer: Response and Survival Positively Associated With HPV16 Copy Number J. Clin. Oncol., July 1, 2008; 26(19): 3138 - 3146. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sabir, R. Schor-Bardach, C. J. Wilcox, S. Rahmanuddin, M. B. Atkins, J. B. Kruskal, S. Signoretti, V. D. Raptopoulos, and S. N. Goldberg Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy Am. J. Roentgenol., July 1, 2008; 191(1): 133 - 139. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Borner, D. Koeberle, R. Von Moos, P. Saletti, D. Rauch, V. Hess, A. Trojan, D. Helbling, B. Pestalozzi, C. Caspar, et al. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK Ann. Onc., July 1, 2008; 19(7): 1288 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Dieras, S. Limentani, G. Romieu, M. Tubiana-Hulin, A. Lortholary, P. Kaufman, V. Girre, M. Besenval, and V. Valero Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy Ann. Onc., July 1, 2008; 19(7): 1255 - 1260. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Theodore, I. Skoneczna, I. Bodrogi, M. Leahy, J. M. Kerst, L. Collette, K. Ven, S. Marreaud, R. D. T. Oliver, and for the EORTC Genito-Urinary Tract Cancer Group A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992) Ann. Onc., July 1, 2008; 19(7): 1304 - 1307. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ohe, Y. Ichinose, K. Nakagawa, T. Tamura, K. Kubota, N. Yamamoto, S. Adachi, Y. Nambu, T. Fujimoto, Y. Nishiwaki, et al. Efficacy and Safety of Two Doses of Pemetrexed Supplemented with Folic Acid and Vitamin B12 in Previously Treated Patients with Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2008; 14(13): 4206 - 4212. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-S. Tham, L. Wang, R. A. Soo, S.-C. Lee, H.-S. Lee, W.-P. Yong, B.-C. Goh, and N. H.G. Holford A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., July 1, 2008; 14(13): 4213 - 4218. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Mohamed, K Yasufuku, T Nakajima, K Hiroshima, R Kubo, A Iyoda, S Yoshida, M Suzuki, Y Sekine, K Shibuya, et al. Analysis of cell cycle-related proteins in mediastinal lymph nodes of patients with N2-NSCLC obtained by EBUS-TBNA: relevance to chemotherapy response Thorax, July 1, 2008; 63(7): 642 - 647. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. LoRusso, S. F. Jones, K. M. Koch, N. Arya, R. A. Fleming, J. Loftiss, L. Pandite, S. Gadgeel, B. L. Weber, and H. A. Burris III Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer J. Clin. Oncol., June 20, 2008; 26(18): 3051 - 3056. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Gomez, D. C. Doval, M. A. Chavez, P. C.-S. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W.C. Chow, M. C. Arbushites, et al. Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer J. Clin. Oncol., June 20, 2008; 26(18): 2999 - 3005. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston, and I. E. Smith Platinum-based chemotherapy in triple-negative breast cancer Ann. Onc., June 20, 2008; (2008) mdn395v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Asomaning, A. E. Reid, W. Zhou, R. S. Heist, R. Zhai, L. Su, E. L. Kwak, L. Blaszkowsky, A. X. Zhu, D. P. Ryan, et al. MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 4010 - 4015. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Rothenberg, J. V. Cox, C. Butts, M. Navarro, Y.-J. Bang, R. Goel, S. Gollins, L. L. Siu, S. Laguerre, and D. Cunningham Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study Ann. Onc., June 10, 2008; (2008) mdn370v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. B. Brunner, M. Geiger, G. G. Grabenbauer, M. Lang-Welzenbach, T. S. Mantoni, A. Cavallaro, R. Sauer, W. Hohenberger, and W. G. McKenna Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer J. Clin. Oncol., June 1, 2008; 26(16): 2699 - 2706. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Yang, C.-J. Yu, J.-Y. Shih, Y.-C. Chang, F.-C. Hu, M.-C. Tsai, K.-Y. Chen, Z.-Z. Lin, C.-J. Huang, C.-T. Shun, et al. Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non-Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy J. Clin. Oncol., June 1, 2008; 26(16): 2745 - 2753. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Kim, N.-H. Park, H. H. Chung, J. W. Kim, Y.-S. Song, and S.-B. Kang Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin? Jpn. J. Clin. Oncol., June 1, 2008; 38(6): 445 - 450. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Quinkler, S. Hahner, S. Wortmann, S. Johanssen, P. Adam, C. Ritte, C. Strasburger, B. Allolio, and M. Fassnacht Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2057 - 2062. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Weiss, L. T. Bemis, E. Nakajima, M. Sugita, D. K. Birks, W. A. Robinson, M. Varella-Garcia, P. A. Bunn Jr, J. Haney, B. A. Helfrich, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines Ann. Onc., June 1, 2008; 19(6): 1053 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. B. J. van Iersel, H. Gelderblom, A. L. Vahrmeijer, E. L. van Persijn van Meerten, F. G. J. Tijl, H. Putter, H. H. Hartgrink, P. J. K. Kuppen, J. W. R. Nortier, R. A. E. M. Tollenaar, et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients Ann. Onc., June 1, 2008; 19(6): 1127 - 1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Hotte, H. W. Hirte, E. X. Chen, L. L. Siu, L. H. Le, A. Corey, A. Iacobucci, M. MacLean, L. Lo, N. L. Fox, et al. A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies Clin. Cancer Res., June 1, 2008; 14(11): 3450 - 3455. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Ramalingam, M. J. Egorin, R. K. Ramanathan, S. C. Remick, R. P. Sikorski, T. F. Lagattuta, G. S. Chatta, D. M. Friedland, R. G. Stoller, D. M. Potter, et al. A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies Clin. Cancer Res., June 1, 2008; 14(11): 3456 - 3461. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Veltkamp, R. S. Jansen, S. Callies, D. Pluim, C. M. Visseren-Grul, H. Rosing, S. Kloeker-Rhoades, V. A.M. Andre, J. H. Beijnen, C. A. Slapak, et al. Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study Clin. Cancer Res., June 1, 2008; 14(11): 3477 - 3486. [Abstract] [Full Text] [PDF] |
||||
![]() |
P K JULKA, D C DOVAL, S GUPTA, and G K RATH Response assessment in solid tumours: a comparison of WHO, SWOG and RECIST guidelines Br. J. Radiol., June 1, 2008; 81(966): 444 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kim, E. Fox, K. Warren, S. M. Blaney, S. L. Berg, P. C. Adamson, M. Libucha, E. Byrley, F. M. Balis, and B. C. Widemann Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials Oncologist, June 1, 2008; 13(6): 679 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations Ann. Onc., May 29, 2008; (2008) mdn352v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. von Mehren, R. J. Schilder, J. D. Cheng, E. Temmer, T. M. Cardoso, F. G. Renshaw, E. Bayever, P. Zannikos, Z. Yuan, and R. B. Cohen A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies Ann. Onc., May 22, 2008; (2008) mdn363v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Llovet, A. M. Di Bisceglie, J. Bruix, B. S. Kramer, R. Lencioni, A. X. Zhu, M. Sherman, M. Schwartz, M. Lotze, J. Talwalkar, et al. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma J Natl Cancer Inst, May 21, 2008; 100(10): 698 - 711. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Socinski, A. W. Blackstock, J. A. Bogart, X. Wang, M. Munley, J. Rosenman, L. Gu, G. A. Masters, P. Ungaro, A. Sleeper, et al. Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non-Small-Cell Lung Cancer: CALGB 30105 J. Clin. Oncol., May 20, 2008; 26(15): 2457 - 2463. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kelly, K. Chansky, L. E. Gaspar, K. S. Albain, J. Jett, Y. C. Ung, D. H.M. Lau, J. J. Crowley, and D. R. Gandara Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non-Small-Cell Lung Cancer: SWOG S0023 J. Clin. Oncol., May 20, 2008; 26(15): 2450 - 2456. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. Sequist, R. G. Martins, D. Spigel, S. M. Grunberg, A. Spira, P. A. Janne, V. A. Joshi, D. McCollum, T. L. Evans, A. Muzikansky, et al. First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations J. Clin. Oncol., May 20, 2008; 26(15): 2442 - 2449. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Rader, C. F. Aylsworth, D. A. Juckett, D. G. Mutch, M. A. Powell, L. Lippmann, and N. V. Dimitrov Phase I Study and Preliminary Pharmacology of the Novel Innate Immune Modulator rBBX-01 in Gynecologic Cancers Clin. Cancer Res., May 15, 2008; 14(10): 3089 - 3097. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lanuti, G. Liu, J. M. Goodwin, R. Zhai, B. C. Fuchs, K. Asomaning, L. Su, N. S. Nishioka, K. K. Tanabe, and D. C. Christiani A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome Clin. Cancer Res., May 15, 2008; 14(10): 3216 - 3222. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rom, G. von Minckwitz, W. Eiermann, M. Sievert, B. Schlehe, F. Marme, F. Schuetz, A. Scharf, M. Eichbaum, H.-P. Sinn, et al. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study Ann. Onc., May 13, 2008; (2008) mdn280v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ravaud, R. Hawkins, J. P. Gardner, H. von der Maase, N. Zantl, P. Harper, F. Rolland, B. Audhuy, J.-P. Machiels, F. Petavy, et al. Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial J. Clin. Oncol., May 10, 2008; 26(14): 2285 - 2291. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study J. Clin. Oncol., May 10, 2008; 26(14): 2320 - 2326. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark, and F. A. Shepherd Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J. Clin. Oncol., May 10, 2008; 26(14): 2350 - 2357. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Zucali, M. G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. L. Ceresoli, J. A. Rodriguez, I. Garassino, P. Comoglio, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann. Onc., May 7, 2008; (2008) mdn240v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kandioler, G. Stamatis, W. Eberhardt, S. Kappel, S. Zochbauer-Muller, I. Kuhrer, M. Mittlbock, R. Zwrtek, C. Aigner, C. Bichler, et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1036 - 1041. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Galsky, M. Eisenberger, S. Moore-Cooper, W. K. Kelly, S. F. Slovin, A. DeLaCruz, Y. Lee, I. J. Webb, and H. I. Scher Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer J. Clin. Oncol., May 1, 2008; 26(13): 2147 - 2154. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Adjei, R. B. Cohen, W. Franklin, C. Morris, D. Wilson, J. R. Molina, L. J. Hanson, L. Gore, L. Chow, S. Leong, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers J. Clin. Oncol., May 1, 2008; 26(13): 2139 - 2146. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Nole, E. Munzone, L. Zorzino, I. Minchella, M. Salvatici, E. Botteri, M. Medici, E. Verri, L. Adamoli, N. Rotmensz, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications Ann. Onc., May 1, 2008; 19(5): 891 - 897. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Kohne, J. De Greve, J. T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Muller, J. Janssens, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015 Ann. Onc., May 1, 2008; 19(5): 920 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Glimelius, H. Sorbye, L. Balteskard, P. Bystrom, P. Pfeiffer, K. Tveit, R. Heikkila, N. Keldsen, M. Albertsson, H. Starkhammar, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer Ann. Onc., May 1, 2008; 19(5): 909 - 914. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Cullen, P. Zatloukal, S. Sorenson, S. Novello, J. R. Fischer, A. A. Joy, M. Zereu, P. Peterson, C. M. Visseren-Grul, and N. Iscoe A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer Ann. Onc., May 1, 2008; 19(5): 939 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Burtness, J. Manola, R. Axelrod, A. Argiris, and A. A. Forastiere A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study Ann. Onc., May 1, 2008; 19(5): 977 - 983. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schlom, J. L. Gulley, and P. M. Arlen Paradigm Shifts in Cancer Vaccine Therapy Experimental Biology and Medicine, May 1, 2008; 233(5): 522 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-M. Baek, J.-H. Chen, O. Nalcioglu, and M.-Y. Su Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy Ann. Onc., May 1, 2008; 19(5): 1022 - 1024. [Full Text] [PDF] |
||||
![]() |
C. C. Portera, J. M. Walshe, D. R. Rosing, N. Denduluri, A. W. Berman, U. Vatas, M. Velarde, C. K. Chow, S. M. Steinberg, D. Nguyen, et al. Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2710 - 2716. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Reiser, J. Wang, L. Chong, W. J. Watkins, A. S. Ray, R. Shibata, G. Birkus, T. Cihlar, S. Wu, B. Li, et al. GS-9219--A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non-Hodgkin's Lymphoma Clin. Cancer Res., May 1, 2008; 14(9): 2824 - 2832. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Sato, R. J. Lewandowski, M. F. Mulcahy, B. Atassi, R. K. Ryu, V. L. Gates, A. A. Nemcek Jr, O. Barakat, A. Benson III, R. Mandal, et al. Unresectable Chemorefractory Liver Metastases: Radioembolization with 90Y Microspheres--Safety, Efficacy, and Survival Radiology, May 1, 2008; 247(2): 507 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. |













